LYMPHOMA, B-CELL

This early-stage study tests a new treatment called UB-VV111 given with the drug rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have returned or not responded to standard therapy. The study will enroll about 10…

This early-stage trial tests a new drug called BTM-3566 in adults with B-cell lymphoma that has come back or stopped responding to treatment. The main goals are to check safety, find the right dose, and see if the drug can slow or stop the cancer. Participants take the drug in 14…

This study tests a new treatment called JNJ-90014496 (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified to better find and attack cancer cells. The goa…

This study tests a new cell therapy called ronde-cel, which targets two markers (CD19 and CD20) on cancer cells, against the usual single-target CAR T therapy for people with large B-cell lymphoma that has returned or not responded to first treatment. About 400 participants will …

This early-stage study tests two new drugs (iberdomide and CC-99282) added to standard chemotherapy for people with untreated aggressive B-cell lymphoma. The goal is to find the safest dose and see if the combinations help shrink tumors. About 224 adults will take part across mul…

This study tests a new drug called STP938 in adults with B-cell or T-cell lymphoma that has returned or not responded to at least two prior treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 180 participants will take the drug alone, first in…

This study looks at whether adding early palliative care to usual treatment helps people with multiple myeloma or aggressive lymphoma feel better. About 144 patients and their caregivers will either get early palliative care or standard care alone. Researchers will track quality …

This study watches how older patients (age 60 and up) with certain blood cancers handle standard CAR-T cell therapy and how it changes their daily life and thinking skills. No extra treatment is given—just careful checkups. The goal is to see if patients can complete all planned …

This study is testing whether a new blood test (ctDNA) can safely guide doctors to give less chemotherapy to certain patients with a type of lymphoma called DLBCL. About 40 newly diagnosed patients will receive standard treatment, and those whose blood test shows no cancer halfwa…

This study is testing a new communication training program called Hematolo-GIST for doctors who treat large B-cell lymphoma. The goal is to help doctors have better conversations with patients about their diagnosis and future care plans. The study will enroll 48 people, including…

This study looks at whether CAR-T cell therapy, a new immune treatment for blood cancers, can cause early heart problems. Researchers will use ultrasound to check the heart function of 60 patients before and within a few days after treatment. The goal is to find out how often the…

This study looks at why some families have more blood cancers like lymphoma, leukemia, and myeloma. Researchers will study the genes and environment of 3000 people who have at least two living relatives with these cancers. The goal is to find inherited factors that raise risk, no…